Valuation : Apellis Pharmaceuticals, Inc.

Market Cap 5.25B 4.52B 4.25B 3.88B 7.28B 500B 7.33B 50.32B 19.58B 253B 19.72B 19.29B 839B P/E 2027 *
342x
P/E 2028 * 38.3x
Enterprise Value 5.25B 4.52B 4.25B 3.88B 7.28B 500B 7.33B 50.32B 19.58B 253B 19.72B 19.29B 839B EV / Sales 2027 *
5.06x
EV / Sales 2028 * 4.35x
Free-Float
88.57%
Yield 2027 *
-
Yield 2028 * -

Last Transcript : Apellis Pharmaceuticals, Inc.

1 day-0.07%
6 months+98.21%
Current year+63.34%
Current year 16.83
Extreme 16.83
41.14
1 year 16.83
Extreme 16.83
41.14
3 years 16.1
Extreme 16.1
73.8
5 years 16.1
Extreme 16.1
94.75
10 years 11.45
Extreme 11.45
94.75
Manager TitleAgeSince
Chief Operating Officer 56 2009-09-24
Director of Finance/CFO 55 2017-09-30
Chief Tech/Sci/R&D Officer - 2025-08-24
Date Insider Type Main position Quantity % Market Cap. Importance
5/14/26 Tender

Director

-63,416 0.0496%
5/14/26 Tender

Director

-297,904 0.2330%
5/14/26 Tender

General Counsel

-928,388 0.7263%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%-.--%+48.82%+1.03% 5.25B
+0.62%-3.55%+38.27%-3.32% 79.79B
+0.43%+1.89%-18.05%-37.01% 58.85B
+1.70%+1.04%+480.16%+24.12% 56.03B
+2.15%-2.13%-1.37%+30.77% 51.26B
+1.39%-0.77%+9.59%+163.65% 47.68B
-0.85%-0.67%+55.16%-18.97% 32.01B
-0.92%-3.72%+43.31%+90.95% 24.98B
-2.12%+2.11%-3.61%+189.46% 23.05B
+1.22%+0.88%+61.13%+115.50% 16.31B
Average +0.01%-0.84%+71.34%+55.62% 39.52B
Weighted average by Cap. +0.19%-1.40%+84.26%+41.01%

Financials

2027 *2028 *
Net sales 1.04B 894M 839M 766M 1.44B 98.76B 1.45B 9.94B 3.87B 50.08B 3.9B 3.81B 166B 1.21B 1.04B 977M 892M 1.68B 115B 1.69B 11.58B 4.51B 58.32B 4.54B 4.44B 193B
Net income -34.31M -29.54M -27.74M -25.32M -47.57M -3.26B -47.91M -329M -128M -1.66B -129M -126M -5.48B 90.71M 78.1M 73.33M 66.94M 126M 8.63B 127M 869M 338M 4.38B 341M 333M 14.49B
Net Debt - -
Logo Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Employees
736
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. APLS Stock